SHOP APOTHEKE EUROPE announces price range for IPO
DGAP-News: Shop Apotheke Europe N.V. / Key word(s): IPO - NO PUBLIC OFFERING - NO INVITATION to subscribe for or purchase securities - NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN. -
SHOP APOTHEKE EUROPE announces price range for IPO - Price range set at EUR 28.00 to EUR 35.00 per share - Targeted gross primary proceeds of c. EUR 100 million - Proceeds are mainly designated to finance growth and market penetration in Continental Europe - Start of offer period after approval and publication of prospectus Venlo/Cologne, 28 September 2016 - SHOP APOTHEKE EUROPE NV ('SHOP APOTHEKE EUROPE' or the 'Company'), one of the leading online pharmacies in Continental Europe, in coordination with Berenberg and Citigroup as Joint Global Coordinators, has set the price range for its initial public offering ('IPO') at EUR 28.00 to EUR 35.00 per share. SHOP APOTHEKE EUROPE intends to raise c. EUR 100 million gross primary proceeds through an offering of up to 3,571,428 newly issued shares (number of shares to be issued dependent on price determined in bookbuilding process in order to achieve envisaged gross proceeds) increasing the Company's current number of shares of 5,498,450. Proceeds from the primary offering are mainly designated to finance SHOP APOTHEKE EUROPE's growth, supporting further growth and market penetration in Continental Europe and to invest in further expansion and automation of its logistics and infrastructure as well as to repay shareholder loans. The final offer price will be determined on the basis of a bookbuilding process still to be undertaken. This announcement does not, and shall not, in any circumstances constitute a public offering, nor an offer to subscribe any securities in any jurisdiction. Purchase orders for shares in the Company can only be submitted and will be only accepted during the offer period The offer period will begin one day after the securities prospectus has been approved by the Dutch Authority for the Financial Markets (AFM), notified to the German Federal Financial Supervisory Authority (BaFin) and published. The approval of such prospectus by the AFM is expected in due course. Detailed information about the IPO will be contained in the SHOP APOTHEKE EUROPE prospectus, which will be published once it has been approved by the AFM and been notified to the German Federal Financial Supervisory Authority (BaFin). Berenberg and Citigroup have been appointed Joint Global Coordinators, and, together with Commerzbank as Joint Bookrunners in connection with the IPO. Lilja & Co. serves as independent advisor to the management and the owners of SHOP APOTHEKE EUROPE. ABOUT SHOP APOTHEKE EUROPE SHOP APOTHEKE EUROPE is one of Continental Europe's leading online pharmacies with a portfolio that focuses on OTC medication and pharmacy-related BPC products. The company operates online pharmacies in Germany, Austria, France, Belgium, Italy, Spain and the Netherlands. In Germany, TÜV-certified shop-apotheke.com is the market leader in terms of traffic, delivering a broad range of approximately 100,000 original products to about 1.5 million active customers quickly and at a good price. In addition, SHOP APOTHEKE EUROPE provides comprehensive and consistent pharmaceutical services. SHOP APOTHEKE EUROPE generated over EUR 125 million in revenues in the financial year 2015. Headquartered in Venlo (Netherlands), SHOP APOTHEKE EUROPE also has an administration site for its sales and marketing units in Cologne (Germany). MEDIA CONTACTS Trade and public media: Financial media: DISCLAIMER. 2016-09-28 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
|